DK175857B1 - Rekombinant retrovirus - Google Patents
Rekombinant retrovirus Download PDFInfo
- Publication number
- DK175857B1 DK175857B1 DK199002268A DK226890A DK175857B1 DK 175857 B1 DK175857 B1 DK 175857B1 DK 199002268 A DK199002268 A DK 199002268A DK 226890 A DK226890 A DK 226890A DK 175857 B1 DK175857 B1 DK 175857B1
- Authority
- DK
- Denmark
- Prior art keywords
- cells
- cell
- vector
- antigen
- recombinant retrovirus
- Prior art date
Links
- 241001430294 unidentified retrovirus Species 0.000 title claims abstract description 71
- 239000013598 vector Substances 0.000 claims abstract description 123
- 238000000034 method Methods 0.000 claims abstract description 68
- 241001465754 Metazoa Species 0.000 claims abstract description 45
- 239000000427 antigen Substances 0.000 claims abstract description 37
- 102000036639 antigens Human genes 0.000 claims abstract description 37
- 108091007433 antigens Proteins 0.000 claims abstract description 37
- 208000015181 infectious disease Diseases 0.000 claims abstract description 28
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 23
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 21
- 230000028993 immune response Effects 0.000 claims abstract description 15
- 230000002458 infectious effect Effects 0.000 claims abstract description 11
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- 230000004936 stimulating effect Effects 0.000 claims abstract description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 3
- 230000003405 preventing effect Effects 0.000 claims abstract description 3
- 230000000087 stabilizing effect Effects 0.000 claims abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 179
- 108090000623 proteins and genes Proteins 0.000 claims description 125
- 102000004169 proteins and genes Human genes 0.000 claims description 62
- 230000001177 retroviral effect Effects 0.000 claims description 61
- 230000014509 gene expression Effects 0.000 claims description 38
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 108010067390 Viral Proteins Proteins 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 5
- 210000000234 capsid Anatomy 0.000 claims description 4
- 230000021633 leukocyte mediated immunity Effects 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 3
- 230000007918 pathogenicity Effects 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 108091026890 Coding region Proteins 0.000 claims description 2
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 abstract description 48
- 241000700605 Viruses Species 0.000 abstract description 30
- 230000009261 transgenic effect Effects 0.000 abstract description 19
- 241000238631 Hexapoda Species 0.000 abstract description 3
- 230000003993 interaction Effects 0.000 abstract description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 39
- 239000012634 fragment Substances 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 24
- 108020004414 DNA Proteins 0.000 description 22
- 239000013612 plasmid Substances 0.000 description 22
- 230000003612 virological effect Effects 0.000 description 21
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 19
- 238000000338 in vitro Methods 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 18
- 239000013603 viral vector Substances 0.000 description 17
- 210000001744 T-lymphocyte Anatomy 0.000 description 14
- 241000714177 Murine leukemia virus Species 0.000 description 13
- 108010078428 env Gene Products Proteins 0.000 description 13
- 230000010354 integration Effects 0.000 description 13
- 239000002245 particle Substances 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 102100034343 Integrase Human genes 0.000 description 12
- 102100034353 Integrase Human genes 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 230000002950 deficient Effects 0.000 description 12
- 230000001566 pro-viral effect Effects 0.000 description 12
- 241000701161 unidentified adenovirus Species 0.000 description 11
- 230000027455 binding Effects 0.000 description 10
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 9
- 102100034349 Integrase Human genes 0.000 description 9
- 108010061833 Integrases Proteins 0.000 description 9
- 238000003780 insertion Methods 0.000 description 9
- 230000006798 recombination Effects 0.000 description 9
- 230000010076 replication Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 101710091045 Envelope protein Proteins 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 101710188315 Protein X Proteins 0.000 description 8
- 230000001086 cytosolic effect Effects 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 238000005215 recombination Methods 0.000 description 8
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 7
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 7
- 108700004025 env Genes Proteins 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 208000026350 Inborn Genetic disease Diseases 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 101150030339 env gene Proteins 0.000 description 6
- 208000016361 genetic disease Diseases 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 241000450599 DNA viruses Species 0.000 description 5
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 5
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 5
- 108020004511 Recombinant DNA Proteins 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000002744 homologous recombination Methods 0.000 description 5
- 230000006801 homologous recombination Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 108020005544 Antisense RNA Proteins 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 208000031886 HIV Infections Diseases 0.000 description 4
- 208000037357 HIV infectious disease Diseases 0.000 description 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 4
- 241000700618 Vaccinia virus Species 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 239000003184 complementary RNA Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 4
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000003362 replicative effect Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 3
- 101710132601 Capsid protein Proteins 0.000 description 3
- 101710094648 Coat protein Proteins 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 3
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 101710125418 Major capsid protein Proteins 0.000 description 3
- 101710141454 Nucleoprotein Proteins 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 101710083689 Probable capsid protein Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 108020004566 Transfer RNA Proteins 0.000 description 3
- 206010046865 Vaccinia virus infection Diseases 0.000 description 3
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 3
- 108020000999 Viral RNA Proteins 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 108010038795 estrogen receptors Proteins 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 229960001438 immunostimulant agent Drugs 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 108010089520 pol Gene Products Proteins 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- 208000007089 vaccinia Diseases 0.000 description 3
- QRBLKGHRWFGINE-UGWAGOLRSA-N 2-[2-[2-[[2-[[4-[[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2s,3r,4r,5s)-4-carbamoyl-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)- Chemical compound N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(C)=O)NC(=O)C(C)C(O)C(C)NC(=O)C(C(O[C@H]1[C@@]([C@@H](O)[C@H](O)[C@H](CO)O1)(C)O[C@H]1[C@@H]([C@](O)([C@@H](O)C(CO)O1)C(N)=O)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C QRBLKGHRWFGINE-UGWAGOLRSA-N 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 241000237852 Mollusca Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 101100042796 Mus musculus Smc2 gene Proteins 0.000 description 2
- LTQCLFMNABRKSH-UHFFFAOYSA-N Phleomycin Natural products N=1C(C=2SC=C(N=2)C(N)=O)CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C LTQCLFMNABRKSH-UHFFFAOYSA-N 0.000 description 2
- 108010035235 Phleomycins Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 101100095967 Xenopus laevis smc2 gene Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002743 insertional mutagenesis Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 101150069832 CD2 gene Proteins 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 102000032165 CD4 receptor binding proteins Human genes 0.000 description 1
- 108091010591 CD4 receptor binding proteins Proteins 0.000 description 1
- 101100148606 Caenorhabditis elegans pst-1 gene Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 241000272194 Ciconiiformes Species 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710096438 DNA-binding protein Proteins 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 241000030538 Thecla Species 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009831 antigen interaction Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 238000009516 primary packaging Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 230000004572 zinc-binding Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK200401772A DK200401772A (da) | 1988-03-21 | 2004-11-16 | Rekombinant retrovirus |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17051588A | 1988-03-21 | 1988-03-21 | |
| US17051588 | 1988-03-21 | ||
| PCT/US1989/001139 WO1989009271A1 (en) | 1988-03-21 | 1989-03-20 | Recombinant retroviruses |
| US8901139 | 1989-03-20 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK226890D0 DK226890D0 (da) | 1990-09-20 |
| DK226890A DK226890A (da) | 1990-11-20 |
| DK175857B1 true DK175857B1 (da) | 2005-04-11 |
Family
ID=22620165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK199002268A DK175857B1 (da) | 1988-03-21 | 1990-09-20 | Rekombinant retrovirus |
Country Status (16)
| Country | Link |
|---|---|
| EP (2) | EP0702084B1 (fi) |
| JP (5) | JPH03504079A (fi) |
| CN (1) | CN1038306A (fi) |
| AT (2) | ATE174960T1 (fi) |
| AU (1) | AU651311B2 (fi) |
| CA (1) | CA1341585C (fi) |
| CH (1) | CH684094A5 (fi) |
| DE (2) | DE68929122T2 (fi) |
| DK (1) | DK175857B1 (fi) |
| ES (1) | ES2139810T3 (fi) |
| FI (1) | FI113476B (fi) |
| GB (2) | GB2236753B (fi) |
| GR (1) | GR3032940T3 (fi) |
| IL (1) | IL89701A (fi) |
| NO (1) | NO314596B1 (fi) |
| WO (1) | WO1989009271A1 (fi) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5716826A (en) * | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
| US6133029A (en) * | 1988-03-21 | 2000-10-17 | Chiron Corporation | Replication defective viral vectors for infecting human cells |
| US5662896A (en) | 1988-03-21 | 1997-09-02 | Chiron Viagene, Inc. | Compositions and methods for cancer immunotherapy |
| US5997859A (en) * | 1988-03-21 | 1999-12-07 | Chiron Corporation | Method for treating a metastatic carcinoma using a conditionally lethal gene |
| US5591624A (en) * | 1988-03-21 | 1997-01-07 | Chiron Viagene, Inc. | Retroviral packaging cell lines |
| US6569679B1 (en) | 1988-03-21 | 2003-05-27 | Chiron Corporation | Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene |
| US5614404A (en) * | 1988-06-10 | 1997-03-25 | Theriod Biologics, Incorporated | Self-assembled, defective, non-self-propagating lentivirus particles |
| US5747324A (en) * | 1988-06-10 | 1998-05-05 | Therion Biologics Corporation | Self-assembled, defective, non-self-propagating lentivirus particles |
| US5650148A (en) * | 1988-12-15 | 1997-07-22 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system |
| ATE219519T1 (de) * | 1989-01-23 | 2002-07-15 | Chiron Corp | Rekombinanttherapien für infektionen und hyperproliferative störungen |
| EP0832980B1 (en) * | 1989-01-23 | 2002-06-19 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
| JP3140757B2 (ja) * | 1989-02-06 | 2001-03-05 | デイナ・フアーバー・キヤンサー・インステイテユート | パッケージング欠陥ｈｉｖプロウイルス、細胞系及びその使用 |
| US6673776B1 (en) | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
| US5693622A (en) * | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| EP0466815A4 (en) * | 1989-04-05 | 1992-09-02 | Novacell Corpporation | Infectious targetted replication-defective virion |
| JP4041535B2 (ja) * | 1989-08-18 | 2008-01-30 | オックスフォード バイオメディカ（ユーケー）リミテッド | 標的細胞にベクター構造体を運搬する組換レトロウィルス |
| GB8919607D0 (en) * | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
| US6337209B1 (en) | 1992-02-26 | 2002-01-08 | Glaxo Wellcome Inc. | Molecular constructs containing a carcinoembryonic antigen regulatory sequence |
| EP0497922B1 (en) * | 1989-10-24 | 2002-01-30 | Chiron Corporation | Infective protein delivery system |
| FR2655855B1 (fr) * | 1989-12-20 | 1992-04-10 | Pasteur Institut | Protection genetique d'animaux contre l'infection par le virus leucemogene bovin, et provirus et virus recombinant derive de ce virus. |
| US6706694B1 (en) | 1990-03-21 | 2004-03-16 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
| US6228844B1 (en) | 1991-11-12 | 2001-05-08 | Vical Incorporated | Stimulating vascular growth by administration of DNA sequences encoding VEGF |
| US6555108B1 (en) * | 1990-09-14 | 2003-04-29 | The General Hospital Corporation | Implanting HSV-TK retrovirus producing cells to treat tumors |
| US6537541B1 (en) * | 1990-09-14 | 2003-03-25 | The General Hospital Corporation | Implantation of HSV-TK retrovirus producer cells to destroy glioma |
| AU665176B2 (en) * | 1990-09-21 | 1995-12-21 | Novartis Vaccines And Diagnostics, Inc. | Packaging cells |
| US5665362A (en) * | 1990-09-25 | 1997-09-09 | Cantab Pharmaceuticals Research Limited | Viral vaccines |
| US5837261A (en) * | 1990-09-25 | 1998-11-17 | Cantab Pharmaceuticals Research Limited | Viral vaccines |
| DE69132311T2 (de) * | 1990-09-25 | 2000-12-14 | Cantab Pharmaceuticals Research Ltd., Cambridge | Bei einer transkomplementenden zellinie erzeugter defektiver virenimpfstoff |
| US7374768B1 (en) | 1990-09-25 | 2008-05-20 | Xenova Research Limited | Viral vaccines |
| GB9100612D0 (en) * | 1991-01-11 | 1991-02-27 | Univ Edinburgh | Method of altering the metabolic state of non-dividing cells,transgenic animals and therapeutic agents |
| GB9104165D0 (en) * | 1991-02-27 | 1991-04-17 | Wellcome Found | Novel entities for hiv therapy |
| GB9107631D0 (en) * | 1991-04-10 | 1991-05-29 | British Bio Technology | Proteinaceous particles |
| WO1993000103A1 (en) * | 1991-06-21 | 1993-01-07 | The Wistar Institute Of Anatomy And Biology | Chimeric envelope proteins for viral targeting |
| AU2512792A (en) * | 1991-08-30 | 1993-04-05 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Defective interfering hiv particles with chimeric cd4-env |
| EP0564645B1 (fr) * | 1991-10-30 | 1999-12-29 | Universite Pierre Et Marie Curie Paris Vi | Cellules transformees pour la prevention ou le traitement de maladies induites par des virus, notamment retrovirus pathogenes |
| WO1993010218A1 (en) * | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB2269175A (en) * | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| US7223411B1 (en) | 1992-07-31 | 2007-05-29 | Dana-Farber Cancer Institute | Herpesvirus replication defective mutants |
| CA2148934C (en) * | 1992-11-09 | 2005-08-02 | French W. Anderson | Targetable vector particles |
| WO1994016072A1 (en) * | 1993-01-14 | 1994-07-21 | Intracell Therapeutics, Inc. | Vectors useful for controlling hiv-1 replication and methods for using the same |
| EP0729511A1 (en) | 1993-11-18 | 1996-09-04 | Chiron Corporation | Compositions and methods for utilizing conditionally lethal genes |
| US6451571B1 (en) | 1994-05-02 | 2002-09-17 | University Of Washington | Thymidine kinase mutants |
| JPH10503641A (ja) * | 1994-05-02 | 1998-04-07 | ユニバーシティ オブ ワシントン | チミジンキナーゼ変異体 |
| US5888814A (en) * | 1994-06-06 | 1999-03-30 | Chiron Corporation | Recombinant host cells encoding TNF proteins |
| AU2648295A (en) * | 1994-06-07 | 1996-01-04 | Immunomedics Inc. | Safe retroviral vectors, their production and use |
| GB9414652D0 (en) * | 1994-07-20 | 1994-09-07 | Moeller Erna | Method of treatment |
| WO1997015679A1 (en) * | 1995-10-27 | 1997-05-01 | The Trustees Of The University Of Pennsylvania | Recombinant viruses containing mobile genetic elements and methods of use in gene therapy |
| FR2741358B1 (fr) * | 1995-11-17 | 1998-01-02 | Centre Nat Rech Scient | Production de vecteurs retroviraux par l'intermediaire de vecteurs viraux a base de virus a adn |
| US6455247B1 (en) | 1996-01-23 | 2002-09-24 | Board Of Trustees Of The Leland Stanford Junior University | Methods for screening for transdominant effector peptides and RNA molecules |
| US6365344B1 (en) | 1996-01-23 | 2002-04-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening for transdominant effector peptides and RNA molecules |
| US6776986B1 (en) | 1996-06-06 | 2004-08-17 | Novartis Ag | Inhibition of HIV-1 replication by antisense RNA expression |
| DE69737597D1 (de) * | 1996-07-22 | 2007-05-24 | Us Gov Health & Human Serv | Vektoren zur inhibierung von viralem und tumorwachstum |
| US6953687B1 (en) | 1997-07-17 | 2005-10-11 | The United States Of America As Represented By The Department Of Health And Human Services | Vectors for delivering viral and oncogenic inhibitors |
| US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
| GB9703802D0 (en) * | 1997-02-24 | 1997-04-16 | Kingsman Susan M | Anti-hiv peptides and proteins |
| EP0973538B1 (en) | 1997-04-10 | 2008-03-12 | University of Southern California | Modified proteins which bind extracellular matrix components |
| GB9711578D0 (en) * | 1997-06-04 | 1997-07-30 | Oxford Biomedica Ltd | Novel retroviral vector production systems |
| DE19737442C2 (de) * | 1997-08-22 | 1999-06-24 | Olfert Landt Tib Molbiol Synth | Proteinumhüllte Polyribonukleinsäuren, ein Verfahren zu ihrer Herstellung und ihre Verwendung |
| WO1999011292A2 (en) * | 1997-09-02 | 1999-03-11 | Chiron Corporation | Compositions and methods for treating arthritis utilizing gene therapy |
| DE69841807D1 (de) | 1997-11-06 | 2010-09-16 | Novartis Vaccines & Diagnostic | Neisseriale antigene |
| US6914131B1 (en) | 1998-10-09 | 2005-07-05 | Chiron S.R.L. | Neisserial antigens |
| SG123535A1 (en) | 1998-01-14 | 2006-07-26 | Chiron Srl | Neisseria meningitidis antigens |
| US7078483B2 (en) | 1998-04-29 | 2006-07-18 | University Of Southern California | Retroviral vectors including modified envelope escort proteins |
| NZ508366A (en) | 1998-05-01 | 2004-03-26 | Chiron Corp | Neisseria meningitidis antigens and compositions |
| AU5323599A (en) | 1998-07-29 | 2000-02-21 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Use of constitutive transport elements for host range control |
| US6399354B1 (en) | 1998-07-31 | 2002-06-04 | President And Fellows Of Harvard College | Replication-competent virus expressing a detectable fusion protein |
| US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| JP2002533124A (ja) | 1998-12-31 | 2002-10-08 | カイロン コーポレイション | Ｈｉｖポリペプチドの改善された発現およびウイルス様粒子の生成 |
| JP2003518363A (ja) | 1999-04-30 | 2003-06-10 | カイロン エセ．ピー．アー． | 保存されたナイセリア抗原 |
| GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
| GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
| PT2169073E (pt) * | 1999-10-11 | 2014-02-20 | Pasteur Institut | Vectores para a preparação de composições imunoterapêuticas |
| US8734812B1 (en) | 1999-10-29 | 2014-05-27 | Novartis Ag | Neisserial antigenic peptides |
| PT1248647E (pt) | 2000-01-17 | 2010-11-18 | Novartis Vaccines & Diagnostics Srl | Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b |
| CN1800385B (zh) | 2000-02-28 | 2010-06-02 | 启龙有限公司 | 奈瑟球菌蛋白质的异源表达 |
| EP2189473A3 (en) | 2000-10-27 | 2010-08-11 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic and proteins from streptococcus groups A & B |
| AU2002235141A1 (en) | 2000-11-27 | 2002-06-03 | Geron Corporation | Glycosyltransferase vectors for treating cancer |
| US20020177571A1 (en) | 2000-11-29 | 2002-11-28 | Gordon Erlinda M. | Targeted vectors for cancer immunotherapy |
| FR2820146B1 (fr) * | 2001-01-29 | 2003-06-27 | Centre Nat Rech Scient | Procede d'obtention de cellules d'encapsidation fortement productrices de retrovirus par elimination, au sein de la culture, des cellules permissives a l'infection par le retro virus produit |
| GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
| GB0111442D0 (en) * | 2001-05-10 | 2001-07-04 | Isis Innovation | Method for preparing recombinant virus |
| AU2002320314A1 (en) | 2001-07-05 | 2003-01-21 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| JP4302513B2 (ja) | 2001-07-05 | 2009-07-29 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 抗原性ｂ型ｈｉｖポリペプチドおよび／または抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、それらのポリペプチドおよびそれらの使用 |
| EP2335724A1 (en) | 2001-12-12 | 2011-06-22 | Novartis Vaccines and Diagnostics S.r.l. | Immunisation against chlamydia trachomatis |
| GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
| US20070178066A1 (en) | 2003-04-21 | 2007-08-02 | Hall Frederick L | Pathotropic targeted gene delivery system for cancer and other disorders |
| EP2353389B1 (en) | 2003-04-21 | 2015-11-04 | Epeius Biotechnologies Corporation | Compositions for treating disorders |
| CA2561696C (en) | 2004-03-29 | 2013-09-03 | Galpharma Co., Ltd. | Novel modified galectin 9 proteins and use thereof |
| GB0606190D0 (en) | 2006-03-28 | 2006-05-10 | Isis Innovation | Construct |
| DK2054431T3 (da) | 2006-06-09 | 2012-01-02 | Novartis Ag | Konformere af bakterielle adhæsiner |
| CN107022217A (zh) * | 2017-06-08 | 2017-08-08 | 南通市乐佳涂料有限公司 | 一种采用水包水的环保抗锈涂料 |
| CN109722465B (zh) * | 2019-01-07 | 2022-02-01 | 福建省疾病预防控制中心(福建省健康教育促进中心、福建省卫生检验检测中心) | 一种hiv耐药检测载体和构建方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2559159B1 (fr) * | 1984-02-02 | 1986-09-12 | Inst Nat Sante Rech Med | Vecteurs viraux de clonage et d'expression d'une proteine dans une cellule eucaryote, comportant au moins une partie du genome d'un retro-virus; cellules eucaryotes transfectees; procede utilisant de telles cellules et proteines obtenues |
| CA1310924C (en) * | 1986-04-24 | 1992-12-01 | Francis P. Mccormick | Infective drug delivery system |
| FR2606030B1 (fr) * | 1986-10-31 | 1989-10-20 | Pasteur Institut | Retrovirus recombinant defectif, son procede de fabrication et ses applications, notamment pour l'etude de l'interaction des retrovirus sauvages avec des lignees cellulaires infectables par celui-ci |
| WO1990001870A1 (en) * | 1988-08-22 | 1990-03-08 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Retroviral vectors expressing soluble cd4; a gene therapy for aids |
-
1989
- 1989-03-20 AU AU33640/89A patent/AU651311B2/en not_active Expired
- 1989-03-20 CN CN89102697A patent/CN1038306A/zh active Granted
- 1989-03-20 WO PCT/US1989/001139 patent/WO1989009271A1/en active IP Right Grant
- 1989-03-20 JP JP1503903A patent/JPH03504079A/ja not_active Withdrawn
- 1989-03-20 CH CH4290/89A patent/CH684094A5/de not_active IP Right Cessation
- 1989-03-21 CA CA005943744A patent/CA1341585C/en not_active Expired - Fee Related
- 1989-03-21 DE DE68929122T patent/DE68929122T2/de not_active Revoked
- 1989-03-21 ES ES95115441T patent/ES2139810T3/es not_active Expired - Lifetime
- 1989-03-21 EP EP95115441A patent/EP0702084B1/en not_active Revoked
- 1989-03-21 EP EP89105059A patent/EP0334301B1/en not_active Expired - Lifetime
- 1989-03-21 AT AT89105059T patent/ATE174960T1/de not_active IP Right Cessation
- 1989-03-21 DE DE68928884T patent/DE68928884T2/de not_active Expired - Fee Related
- 1989-03-21 AT AT95115441T patent/ATE187983T1/de not_active IP Right Cessation
- 1989-03-21 IL IL8970189A patent/IL89701A/en unknown
-
1990
- 1990-09-20 DK DK199002268A patent/DK175857B1/da not_active IP Right Cessation
- 1990-09-20 NO NO19904103A patent/NO314596B1/no not_active IP Right Cessation
- 1990-09-20 GB GB9020586A patent/GB2236753B/en not_active Expired - Lifetime
- 1990-09-20 FI FI904647A patent/FI113476B/fi not_active IP Right Cessation
-
1992
- 1992-08-10 GB GB9217086A patent/GB2255777B/en not_active Expired - Fee Related
-
1998
- 1998-12-24 JP JP10368260A patent/JPH11262397A/ja not_active Withdrawn
-
2000
- 2000-03-10 GR GR20000400636T patent/GR3032940T3/el not_active IP Right Cessation
-
2002
- 2002-03-11 JP JP2002066181A patent/JP2002306188A/ja not_active Withdrawn
-
2003
- 2003-10-10 JP JP2003353011A patent/JP2004008227A/ja active Pending
-
2007
- 2007-08-01 JP JP2007200751A patent/JP2007289206A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK175857B1 (da) | Rekombinant retrovirus | |
| US5888502A (en) | Recombinant retroviruses | |
| CA2066053C (en) | Recombinant retroviruses delivering vector constructs to target cells | |
| US6410326B1 (en) | Method for inhibiting human tumor cells | |
| RU2301260C2 (ru) | Вирусные векторы с зависимой от условий репликацией и их применение | |
| US20040033595A1 (en) | Conditionally replicating vectors for inhibiting viral infections | |
| AU689799B2 (en) | Recombinant retroviruses | |
| Contag et al. | Simian immunodeficiency virus (SIV) from Old World monkeys | |
| AU2001293075B2 (en) | Conditionally replicating viral vectors and their use | |
| GB2254424A (en) | Indicator cells and retroviruses for the detection of gene sequenes | |
| AU2001293075A1 (en) | Conditionally replicating viral vectors and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUP | Patent expired |